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Background: Polymorphisms at codons 307 and 680 are the most commonly encountered allelic variants of the
follicle-stimulating hormone receptor (FSHR) gene. Studies in Caucasians suggest that certain FSHR variants are
more common in women with polycystic ovary syndrome (PCOS) than normal women. The objective of this study
was to determine the distribution of FSHR gene polymorphisms at codons 307 and 680 in Thai women with chronic
anovulation, without (121 women) and with PCOS (133 women), using 132 known fertile women as controls.
Methods: DNA samples from peripheral blood lymphocytes were extracted and analyzed by polymerase chain
reaction-restriction fragment length polymorphism.
Results: The prevalence of Threonine307Threonine (TT), Threonine307Alanine (TA), and Alanine307Alanine (AA)
genotypes at codon 307 was 53.0% (95% CI = 44.2-61.7%), 42.4% (95% CI = 34–51.3%), and 4.5% (95% CI = 1.9-10.1%) in
controls; 52.6% (95% CI = 43.8-61.3%), 39.8% (95% CI = 31.6-48.7%), and 7.5% (95% CI = 3.9-13.7%) in PCOS women; and
50.4% (95% CI = 42.8-61.2%), 45.4% (95% CI = 34.9-53.1%), and 4.5% (95% CI = 1.5-9.6%) in anovulatory women without
PCOS, respectively. The prevalence of Asparagine680Asparagine (NN), Asparagine680Serine (NS), and Serine680Serine (SS)
genotypes at codon 680 was 54.5% (95% CI = 45.7-63.2%), 40.9% (95% CI = 32.5-49.8%), and 4.5% (95% CI = 1.9-10.1%) in
controls; 51.9% (95% CI = 43.1-60.6%), 44.4% (95% CI = 35.8-53.2%), and 3.8% (95% CI = 1.4-9.0%) in PCOS women; and
47.9% (95% CI = 40.4-58.8%), 47.1% (95% CI = 36.5-54.7%), and 5.0% (95% CI = 2–10.9%) in anovulatory women without
PCOS, respectively. The prevalence of FSHR gene polymorphisms at both codons were not statistically different among
the three groups.
Conclusions: In Thai women, there was no association between the FSHR gene polymorphism at codons 307 and 680
and chronic anovulation.
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Chronic anovulation is a common disorder in women of
reproductive age. Some women with chronic anovulation
also have high androgen levels or polycystic ovary appea-
rance on ultrasound examination, and are diagnosed as
having polycystic ovary syndrome (PCOS) by the 2003
Rotterdam criteria [1]. The pathogenesis of chronic ano-
vulation, with or without PCOS, is poorly understood. A
high incidence of similar phenotypes in family members
of PCOS patients suggests that genetics may play a role
[2]. Though the polymorphisms in genes encoding sex
hormones and their receptors have been investigated, re-
sults are still conflicting [3].
Follicle stimulating hormone (FSH) plays an important
role in follicular growth and ovarian steroidogenesis. Muta-
tions or polymorphisms in the FSH receptor (FSHR) gene
can affect reproductive ability [4]. The FSHR gene contains
two important single nucleotide polymorphisms (SNPs) in
exon 10, which are in linkage disequilibrium. One poly-
morphism is located at codon 307 in the extracellular
domain of the receptor, where alanine is replaced by
threonine (A307T; rs6165). The other polymorphism is
in the intracellular domain at codon 680, where aspara-
gine is replaced by serine (N680S; rs6166) [5,6]. To date,
few genetic studies have examined the association between
FSHR polymorphisms and PCOS [7-11]. Sudo et al. [9] re-
ported a significant increase in the A307T and N680S ge-
notypes in a large cohort of Japanese women with PCOS
compared to ovulatory women. Some studies reported that
the S680S genotype in PCOS women was associated with
higher baseline gonadotropic hormone and testosterone
levels [12], as well as clomiphene citrate resistance [13].
Since PCOS prevalence and clinical manifestations, as well
as frequency of the FSHR polymorphisms, can differ be-
tween ethnic and racial groups [14-20], more studies should
be done to confirm this finding.
The objective of this study was to compare the preva-
lence of the FSHR gene polymorphisms at codons 307 and
680 in Thai women with chronic anovulation, with PCOS
(group I) and without PCOS (group II). We used pregnant
women, who had regular cycles and achieved spontaneous
pregnancies within 12 months of unprotected intercourse
as controls (group III). The results of the study could sug-
gest whether the FSHR polymorphisms at these two codons
played a role in chronic anovulation, and whether we could
use them to differentiate chronic anovulatory women with
and without PCOS.
Methods
Study and control population
The study was approved by the Ethics Committee of the
Faculty of Medicine, Chiang Mai University (No. 012/2011,
dated January 7, 2011). Written informed consent, previ-
ously approved by the Institutional Review Board, was readand signed by all participants. The study population con-
sisted of women with chronic anovulation (n = 121) and
PCOS (n = 133), who attended either the gynecologic out-
patient clinic or gynecologic endocrine clinic, Maharaj
Nakorn Chiang Mai University Hospital from January
2012 to August 2013. The controls were 132 pregnant
women, who first visited the antenatal care clinic in their
first trimesters during the same time period as women
with chronic anovulation.
In the anovulation group, women were included if they
were Thai, aged 20 to 40 years, had both ovaries present
on ultrasound scan, had irregular menstrual cycles, and
oligomenorrhea (>35 day intervals between periods), or
amenorrhea (absence of vaginal bleeding for at least
6 months or 3 cycles of normal periods), which was per-
sistent for at least 1 year. They were excluded if they: 1)
used oral contraceptive pills, hormonal intrauterine de-
vices (IUDs) or other hormonal therapy within 3 months
prior to the study; 2) had other endocrine disorders,
such as diabetes mellitus, thyroid diseases, premature ovar-
ian failure, hyperprolactinemia or other known causes of
androgen excess disorders; 3) had language or other com-
munication barriers; 4) had previous history of ovarian sur-
gery; 5) had previous exposure to cytotoxic drugs or pelvic
radiation therapy; and 6) did not consent to participate in
the study. Anovulatory women were classified as having
PCOS if they fulfilled the Rotterdam criteria (1); otherwise
they were classified as having chronic anovulation without
PCOS.
The controls consisted of 132 pregnant women who
fulfilled the following eligibility criteria: Thai women,
aged 20 to 40 years, first attendance at the antenatal care
clinic, had regular menstrual cycles with intervals of 21
to 35 days, and spontaneous pregnancy within 12 months
of attempt. They were excluded if they: 1) had a history
of infertility or any infertility treatment in the past; 2)
had language or other communication barriers; 3) had a
gestational age of ≥10 weeks; and 4) did not consent to
participate in the study.
Evaluations and hormone assays
Anovulatory subjects underwent routine examinations,
which included a detailed history, physical and pelvic
examination, transvaginal ultrasound, and other labora-
tory studies as deemed necessary by the attending gyne-
cologists. In addition, blood samples were obtained for
hormonal studies and DNA analysis. Plasma concentra-
tions of follicle stimulating hormone (FSH), luteinizing
hormone (LH), estradiol (E2), prolactin (PRL), testoster-
one (T), and sex hormone binding globulin (SHBG)
were measured with electrochemiluminescence immu-
noassays (Elecsys®, Roche Diagnostics, Indianapolis, USA).
Plasma concentrations of androstenedione (ADD), 17-
hydroxyprogesterone (17-OHP), dehydroepiandrosterone
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munosorbent Assay (ELISA, NovaTec Immundiagnostica,
GmbH, Germany). Intra- and inter-assay coefficients of
variation of all hormonal assays were <4.5% and <6.5%, re-
spectively. Any patient having 17-OHP levels higher than
4.0 ng/mL received ACTH stimulation test to exclude
late-onset congenital adrenal hyperplasia.
Subjects in the control group had routine physical and
obstetrical examinations, and blood tests as usual for those
attending the antenatal clinic for the first time. In addition,
three milliliters of blood were obtained in tubes containing
ethylenediaminetetraacetic acid for DNA analysis.
Genotyping
DNA was extracted from peripheral blood leukocytes,
using QIAamp DNA kit (QIAGEN, Hilden, Germany),
according to the manufacturer’s instructions, and kept
frozen at −20°C until use. Genotyping was performed
without knowledge of the clinical status of the subjects.
A part of exon 10, from nucleotides 1624 to 2143 of the
FSHR gene, was amplified by Polymerase Chain Reaction
(PCR), using forward and reverse primers as follows: (pri-
mer-1) 5′-TTTGTGGTCATCTGTGGCTGC-3′ and (pri-
mer-2) 5′-CAA AGGCAAGGACTGAATTATCATT-3′.
The PCR reactions were performed in an Eppendorf Per-
sonal Cycler Thermocycler (Eppendorf, Germany) with 5
uL Taq polymerase PCR Master Mix (Invitrogen, USA),
20 pmols of each primer and 100 ng of DNA in a final vol-
ume of 10 μL. The cycling conditions were as follows: ini-
tial denaturation at 94°C for 5 minutes, 30 cycles consisting
of denaturation at 95°C for 30 seconds, annealing at 60°C
for 30 seconds, extension and final elongation at 72°C for
7 minutes. The PCR products were digested with BsrI (Pro-
mega, USA), an endonuclease that recognized the A to G
transition sites. The resulting products were run on 2%
agarose gel electrophoresis, stained with ethidium bromide
and photographed. Three possible patterns were expected
(Figure 1): 1) a single band of undigested products of 520A DNA           SS            SS NS            NS NN            NN D







Figure 1 Agarose gel electrophoresis. (A) Restriction fragment length p
Agarose gel (2.0%) electrophoresis with ethidium bromide staining followin
two bands of 520 and 413-bp for NS, and a 413-bp band for SS, are shown
nucleotide substitutions are indicated by arrows.base pairs in size, indicating homozygous Asn680Asn
(NN); 2) a single band of digested products of 413 base
pairs, indicating homozygous Ser680Ser (SS), and two
bands of 520 and 413 base pairs, representing heterozy-
gous state for Asn680Ser (NS). Ten percent of the samples
were randomly selected for DNA sequencing to confirm
the presence of polymorphisms shown by PCR-Restriction
Fragment Length Polymorphism (PCR-RFLP) analysis.
Detection of the Thr307Ala variant was performed by a
nested PCR-RFLP method. In this case, a second round of
PCR, using a second set of primers that bound to a sec-
ondary target within the first run products, was necessary
to reduce non-specific products generated by the first run
of PCR. The region of exon 10, containing nucleotides
931 to 1587 of the FSHR gene, was first amplified using
forward and reverse primers as follows: (primer-3) 5′-
TCTGAGCTTCATCCAATTTGCA-3′; and (primer-4)
5′-GGGAAAGAGGGCAGCTGCAA-3′. The PCR reac-
tions were performed in an Eppendorf Personal Cycler
Thermocycler with 5 uL Taq polymerase PCR Master
Mix, 20 pmols of each primer and 100 ng of DNA in a
final volume of 10 μL. The cycling conditions were as fol-
lows: initial denaturation at 94°C for 5 minutes, followed
by 10 cycles of denaturation at 94°C for 1 minute, annea-
ling at 62°C for 1 minute, extension at 72°C for 1 minute,
and a final elongation at 72°C for 7 minutes. The PCR
products (657 base pairs of DNA fragments) after the first
round (2 μL) were further amplified by a second set of
primers as follows: (primer-5) 5′-CAAATCTATTTTA
AGGCAAGAAGTTGATTATATGCC TCAG-3′ and (pri-
mer-6) 5′-GTAGATTCCAATGCAGAGATCA-3′. The
PCR cycle was carried out for 1 minute at 94°C for initial
denaturation, followed by 25 cycles of denaturation at 94°
C for 30 seconds, annealing at 60°C for 30 seconds, exten-
sion at 72°C for 30 seconds, and a final elongation step at
72°C for 7 minutes. The final PCR products were digested
with Bsu36I restriction enzyme, which recognized the tran-
sition sites of T to C. Restriction endonuclease digestionB NA                     




olymorphism (RFLP) analysis of the Asn680Ser FSH receptor variant.
g BsrI digestion of the PCR products is shown. A 520-bp band for NN,
. (B) DNA sequencing of each variant PCR products. Positions of the
Singhasena et al. Reproductive Biology and Endocrinology 2014, 12:86 Page 4 of 7
http://www.rbej.com/content/12/1/86products were visualized on 2% agarose gel, stained with
ethidium bromide, and photographed. Three different pat-
terns were possible (Figure 2): 1) a single band of un-
digested products of 364 base pairs in size, indicating a
homozygous state for Thr307Thr (TT); 2) a single band of
digested products of 324 base pairs in size, indicating a
homozygous state for Ala307Ala (AA); and 3) two bands of
364 and 324 base pairs, indicating a heterozygous state for
Thr307Ala (TA). Ten percent of samples were randomly
selected for DNA sequencing to confirm the results ob-
tained from PCR-RFLP analysis.
Statistical analysis
Descriptive statistics (mean ± SD) were used to summarize
baseline characteristics and hormone levels of patients in
the controls and the two study groups. The prevalence of
FSHR polymorphism, and its 95% confidence interval, was
calculated in each group, and compared among groups
using rxc Chi-Square tests. All statistical analyses were
performed using SPSS version 15 for windows (IBM com-
pany, IL, USA). A value of P < 0.05 was considered to indi-
cate statistical significance.
In a previous study in Japanese women [9], the preva-
lence of NS allele in PCOS women was significantly
higher than that in the ovulating group (66.7% versus
43.5%, P < 0.05). Given this difference, and a type I error
of 0.05 (two-tailed) and a power of 80%, we calculated that
a sample size of 71 women would be required per group.
To ensure a sufficient sample size, we planned to recruit
at least 100 subjects with PCOS and 100 controls.
Results
A total of 950 women with oligomenorrhea or amenor-
rhea were screened, and 308 women met the eligibility
criteria for the study. Of these 121/151 and 133/157
women with chronic anovulation and PCOS, respect-
ively, consented to participate in the study. There was
100% agreement between the results obtained by PCR-Figure 2 Agarose gel electrophoresis. (A) Restriction fragment length p
Agarose gel (2.0%) electrophoresis with ethidium bromide staining, followi
bands, 364- and 328-bp, for TA; and a 328-bp band for AA, are shown. (B) DN
substitution are indicated by arrows.RFLP and DNA sequencing in the 10% of random sam-
ples that were sent out for confirmation.
The allelic frequencies for the polymorphisms at co-
dons 307 and 680 in controls, women with PCOS, and
women with chronic anovulation without PCOS are
shown in Table 1. The prevalence of polymorphism ob-
tained at the codons Thr307Ala and Asn680Ser were
similar across all groups. There was no statistical differ-
ence in the frequency distribution of these genotypes at
codon 307 (P = 0.756) or 680 (P = 0.932) among fertile
women and those with anovulation, with or without
PCOS.
There was no statistically significant difference in age,
serum FSH, estradiol, and PRL levels between anovula-
tory women with or without PCOS (Table 2). However,
BMI, serum LH, ADD, DHEAS, 17-OHP, testosterone,
and free androgen index (FAI) were significantly higher
in the PCOS group than the anovulatory group without
PCOS, and serum SHBG level was significantly lower.
Subgroup analysis was performed by pooling anovulatory
subjects with and without PCOS together, and classified
them by their FSHR genotypes (Table 3). When poly-
morphism at codon 307 was considered, there were statis-
tical significant differences in the levels of FSH (P <0.001)
and LH (P = 0.003), but not in their ages, estrogen level or
androgen profiles. In case of the polymorphism at the
codon 680, only the level of LH was statistically different
(P = 0.041).
Discussion
Kuijper et al. [20] reported the distribution of single nu-
cleotide polymorphisms (SNPs) at codon 680 of the FSHR
gene in a large population of infertile patients (1,771
women) from various ethnic backgrounds. Of these, only
3.8% or 67 women were Asians and only 11% of them had
cycle disorders. They found a significantly lower preva-
lence of Ser680Ser FSHR variant (10.4%), and a signifi-
cantly higher prevalence of Asn680Asn variant (50.7%) inolymorphism (RFLP) analysis of the Thr307Ala FSH receptor variant.
ng Bsu36I digestion of the PCR products. A 364-bp band for TT; two
A sequencing of each variant PCR products. Positions of the nucleotide
Table 1 FSHR gene polymorphism at positions 307 and 680 in PCOS, chronic anovulatory, and control women
Position 307 Position 680
Thr/Thr Thr/Ala Ala/Ala Asn/Asn Asn/Ser Ser/Ser
PCOS 52.6% 39.8% 7.5% 51.9% 44.4% 3.8%
(95% CI) (n = 133 women) (43.8%-61.3%) (31.6%-48.7%) (3.9%-13.7%) (43.1%-60.6%) (35.8%-53.2%) (1.4%-9.0%)
Chronic anovulation 50.4% 45.4% 4.5% 47.9% 47.1% 5.0%
(95% CI) (n = 121 women) (42.8%-61.2%) (34.9%-53.1%) (1.5% -9.6%) (40.4%-58.8%) (36.5%-54.7%) (2.0%-10.9%)
Controls 53.0% 42.4% 4.5% 54.5% 40.9% 4.5%
(95% CI) (n = 132 women) (44.2%-61.7%) (34.0%-51.3%) (1.9%-10.1%) (45.7%-63.2%) (32.5%-49.8%) (1.9%-10.1%)
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These findings were compatible with our study in Thai
women. Similar to their study, we found no difference in
FSH concentration among the various FSHR polymor-
phisms at this position. Unlike other previous studies,
where basal FSH and LH levels were measured on cycle
day 2 or 3, we measured random levels of FSH and LH
during the anovulatory period. Interestingly, we found that
serum FSH and LH levels were significantly higher in an-
ovulatory subjects who carried the Thr307Ala or Ala307Ala
genotypes. This finding needs to be confirmed by further
studies in a larger population and from other ethnic groups.
We hypothesized that SNP at this codon, which was in-
volved in FSH binding, could result in a less active receptor.Table 2 Demographics and endocrine profiles of






Age (years) 27.4 ± 5.6 26.6 ± 5.3 0.2092




5.5 ± 3.2 6.1 ± 2.4 0.143
Luteininzing hormone
(mIU/mL)
9.7 ± 7.7 12.2 ± 7.3 0.0100
Estradiol (pg/mL) 106.1 ± 140.1 86.8 ± 130.1 0.2546
Prolactin (ng/mL) 16.8 ± 11.5 15.3 ± 8.8 0.2398
Androstendione (ng/mL) 1.7 ± 1.6 2.5 ± 1.3 <0.0001
Dehydroepiandrosterone
sulfate (ng/mL)
1.4 ± 1.0 2.4 ± 1.3 <0.0001
17-hydroxyprogesterone
(ng/mL)
1.1 ± 1.6 1.6 ± 1.5 0.0052
Testosterone (ng/mL) 0.3 ± 0.1 0.6 ± 0.3 <0.0001
Sex hormone binding
globulin (nmol/L)
69.8 ± 47.4 40.8 ± 29.7 <0.0001
Free androgen
index (FAI)
0.6 ± 0.6 2.6 ± 2.5 <0.0001
Values =mean ± standard deviation.
*t-tests.
PCOS = polycystic ovary syndrome; mIU =milli International Unit; mL =milliliter;
pg = picogram; ng = nanogram; nmol = nanomol; L = liter.As a consequence, a higher amount of FSH was required
to generate the same downstream effect as a woman with
Thr307Thr genotype (wild type). The increase in FSH
level was probably driven by an increase in hypothalamic
gonadotropin releasing hormone activity, which concomi-
tantly resulted in a higher LH secretion. The slight in-
crease in gonadotropin levels was probably not clinically
significant under normal physiological conditions, as the
distribution of FSHR polymorphisms was not different
among fertile controls with regular cycles and those with
chronic anovulation. However, polymorphisms at these
two codons could interact with polymorphisms of other
genes that were involved in steroid productions and folli-
culogenesis, and resulted in anovulation or an abnormal
response to ovarian stimulation during an assisted con-
ception treatment.
In a study of 522 Japanese women, Sudo et al. [9] found
significantly higher prevalence of Asn680Ser genotypes in
Japanese PCOS women than in those who had regular
ovulation. However, their study contained only 18 PCOS
women. Our study, which consisted of 133 Thai PCOS
women, did not confirm their findings. Conway et al. [7]
also reported no difference in the prevalence of Thr307/
Ser680 allelic variants of FSHR gene among 93 British
PCOS women and 51 controls.
In Dutch women, Laven et al. [21] reported a signifi-
cantly lower prevalence of Thr307Thr genotype and signifi-
cantly higher prevalence of the Ser680Ser polymorphism in
148 anovulatory infertile women (61 of whom had PCOS)
than controls. Our study, with 254 anovulatory women, did
not confirm their findings. This discrepancy could be due
to the difference in ethnic group, clinical presentation, or
simply because of random errors as they had fewer cases
and only 30 controls. Indeed, another recent study involv-
ing 580 anovulatory Dutch women, of whom 518 were di-
agnosed with PCOS and 2,996 unselected controls from
the general population, could not find any difference in the
distribution of FSHR genotypes at position 680 [12]. On
the other hand, a recent meta-analysis in women with
PCOS showed that the FSHR Ala307/Ser680 genotype was
associated with an increased risk, while homozygous for
Asn680Asn showed a significant reduction in PCOS risk
Table 3 Anovulatory subjects (with and without PCOS) classified by FSHR genotypes at codon position 307 or 680
Variable Polymorphism at codon 307 Polymorphism at codon 680
TT (n = 131) TA (n = 108) AA (n = 15) P* NN (n = 127) NS (n = 116) SS (n = 11) P*
Age (range) in year 27.0 (20–40) 26.5 (20–40) 28.4 (20–38) 0.419 27.1 (20–40) 26.6 (20–38) 27.9 (21–40) 0.639
Serum hormone
FSH (mIU/mL) 5.4 ± 2.6 6.2 ± 2.9 9.2 ± 9.7 0.000 5.5 ± 2.5 6.5 ± 4.5 5.8 ± 2.7 0.106
LH (mIU/mL) 9.4 ± 6.2 12.6 ± 8.6 12.7 ± 6.6 0.003 9.9 ± 6.8 12.3 ± 8.2 9.2 ± 7.0 0.041
Estradiol (pg/mL) 92.7 ± 138.3 93.9 ± 106.6 95.3 ± 121.1 0.995 91.8 ± 137.7 97.6 ± 113.2 61.5 ± 46.7 0.646
Prolactin (ng/mL) 16.5 ± 10.8 16.4 ± 11.5 13.9 ± 7.4 0.694 16.5 ± 10.8 15.9 ± 11.1 17.8 ± 9.8 0.822
ADD (ng/mL) 2.1 ± 1.2 2.1 ± 1.3 2.4 ± 1.1 0.653 2.1 ± 1.2 2.1 ± 1.2 2.0 ± 1.5 0.938
DHEAS (ng/mL) 2.1 ± 1.3 2.2 ± 1.6 2.9 ± 2.3 0.124 2.1 ± 1.4 2.3 ± 1.7 1.6 ± 0.9 0.169
17-OHP (ng/mL) 1.3 ± 1.4 1.2 ± 0.9 1.5 ± 0.9 0.680 1.3 ± 1.4 1.3 ± 0.9 0.9 ± 0.7 0.463
Testosterone (ng/mL) 0.5 ± 0.3 0.5 ± 0.4 0.5 ± 0.4 0.233 0.5 ± 0.3 0.6 ± 0.4 0.3 ± 0.2 0.067
SHBG (nmol/L) 52.5 ± 43.3 56.4 ± 41.5 30.7 ± 15.0 0.474 52.7 ± 42.8 55.5 ± 43.3 46.5 ± 25.6 0.826
*oneway ANOVA test.
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cluded studies, with 18, 50 and 93 PCOS women, showed a
significant difference in genotype profiles. If our study was
included in this meta-analysis, results would shift direction
toward no association.
The difference in androgen profiles between anovulatory
women with and without PCOS in our study was most
likely due to classification bias, as hyperandrogenemia is
one of the diagnostic criteria for PCOS. In addition, the
higher BMI and LH were common features, although not
unique, in PCOS cases.
Although our study did not show any difference in the
distribution of FSHR genotypes at positions 307 and 680, it
was possible that a very small difference could exist. Our
calculation showed we had a statistical power of 20.6%
(given a Type I error of 5%, two-tailed) to show a significant
difference between the prevalence of 4.5% versus 7.5% in
Ala/Ala genotype at position 307 in the chronic anovula-
tion and the PCOS group, respectively. A larger sample size
of 1,200 or more women with chronic anovulation, with or
without PCOS, will need to be recruited to ascertain that
there was no subtle genotype difference between groups at
this position.
The strength of our study was that we used hormonal
profiles and ultrasound, in addition to more subjective
clinical signs and symptoms, to classify chronic anovula-
tory patients into those with and without PCOS. We iden-
tified SNPs using PCR-RFLP, which is known to have a
very high diagnostic accuracy [23,24] , and we randomly
confirmed our PCR-RFLP results by sequencing.
Conclusions
This was the first study to report FSHR polymorphisms
at position 307 and 680 in Thai women with chronic
anovulation, with and without PCOS, compared to nor-
mal fertile controls with regular ovulation. In contrast toa previous study in Japanese women, we found no asso-
ciation between FSHR gene polymorphisms at positions
307 and 680 and chronic anovulation, or PCOS.
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